NGEN-OS Trademark

Trademark Overview

On Monday, December 21, 2020, a trademark application was filed for NGEN-OS with the United States Patent and Trademark Office. The USPTO has given the NGEN-OS trademark a serial number of 90398276. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 2, 2023. This trademark is owned by Omega Therapeutics, Inc.. The NGEN-OS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals; none of the foregoing relating to human growth hormones, mutation detection reagents, genome editing reagents, polynucleotide assembly reagents, or endocrine diseases and disorders
ngen-os

General Information

Serial Number90398276
Word MarkNGEN-OS
Filing DateMonday, December 21, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 2, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 5, 2022

Trademark Statements

Goods and ServicesResearch and development in the field of computational biology, bioinformatics, biotechnology and pharmaceuticals; none of the foregoing relating to human growth hormones, mutation detection reagents, genome editing reagents, polynucleotide assembly reagents, or endocrine diseases and disorders

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, November 13, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOmega Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02141
Party NameOmega Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events

Event DateEvent Description
Monday, October 2, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 2, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, June 1, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 1, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, June 1, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 24, 2023SOU EXTENSION 1 GRANTED
Friday, February 24, 2023SOU EXTENSION 1 FILED
Friday, February 24, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 30, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 5, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 5, 2022PUBLISHED FOR OPPOSITION
Wednesday, June 15, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 23, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 23, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, May 10, 2022NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Tuesday, May 10, 2022ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Tuesday, May 10, 2022ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Monday, April 4, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 4, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, December 6, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, December 6, 2021FINAL REFUSAL E-MAILED
Monday, December 6, 2021FINAL REFUSAL WRITTEN
Saturday, November 13, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 12, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 12, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 11, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 11, 2021NON-FINAL ACTION E-MAILED
Tuesday, May 11, 2021NON-FINAL ACTION WRITTEN
Sunday, May 9, 2021ASSIGNED TO EXAMINER
Friday, March 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

ngen reagents genome detection mutation hormones editing polynucleotide disorders diseases endocrine